Cargando…

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive cancer showing a very poor prognosis because of metastasis formation at an early stage and acquisition of chemoresistance. One key driver of chemoresistance is the transcription factor Forkhead box protein M1 (FOXM1) that regulates cell cycle proliferat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taromi, Sanaz, Lewens, Florentine, Arsenic, Ruza, Sedding, Dagmar, Sänger, Jörg, Kunze, Almut, Möbs, Markus, Benecke, Joana, Freitag, Helma, Christen, Friederike, Kaemmerer, Daniel, Lupp, Amelie, Heilmann, Mareike, Lammert, Hedwig, Schneider, Claus-Peter, Richter, Karen, Hummel, Michael, Siegmund, Britta, Burger, Meike, Briest, Franziska, Grabowski, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722545/ https://www.ncbi.nlm.nih.gov/pubmed/29228593 http://dx.doi.org/10.18632/oncotarget.21221

Ejemplares similares

FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors
por: Briest, Franziska, et al.
Publicado: (2015)

Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment
por: Busse, Antonia, et al.
Publicado: (2020)

Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas
por: Kaemmerer, Daniel, et al.
Publicado: (2017)

Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data
por: Rösner, Erik, et al.
Publicado: (2022)

Immunohistochemical analysis of PDK1 expression in breast cancer
por: Arsenic, Ruza
Publicado: (2014)

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models
por: Nölting, Svenja, et al.
Publicado: (2017)

Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours
por: Rösner, Erik, et al.
Publicado: (2021)

Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61
por: Ehms, Blanca, et al.
Publicado: (2022)

Co-Expression of Adaptor Protein FAM159B with Different Markers for Neuroendocrine Cells: An Immunocytochemical and Immunohistochemical Study
por: Beyer, Anna-Sophia Liselott, et al.
Publicado: (2022)

Immunohistochemical Evaluation of Adaptor Protein FAM159B Expression in Normal and Neoplastic Human Tissues
por: Beyer, Anna-Sophia Lieselott, et al.
Publicado: (2021)

Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo
por: Briest, Franziska, et al.
Publicado: (2020)

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
por: Arsenic, Ruza, et al.
Publicado: (2015)

Comprehensive Assessment of GPR68 Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody
por: Herzig, Markus, et al.
Publicado: (2019)

Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT
por: Kaemmerer, Daniel, et al.
Publicado: (2011)

Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects
por: Neubauer, Elisa, et al.
Publicado: (2016)

Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissues
por: Nürge, Benjamin, et al.
Publicado: (2021)

Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies
por: Czajkowski, Max, et al.
Publicado: (2022)

Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015)

Expression of the Calcitonin Receptor-like Receptor (CALCRL) in Normal and Neoplastic Tissues
por: Wende, Benjamin, et al.
Publicado: (2023)

Expression of G protein-coupled receptor GPR19 in normal and neoplastic human tissues
por: Gerlach, Lorena, et al.
Publicado: (2023)

Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019)

Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets
por: Kaemmerer, Daniel, et al.
Publicado: (2017)

PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms
por: Briest, Franziska, et al.
Publicado: (2014)

Assessment of G Protein-Coupled Oestrogen Receptor Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody
por: Bubb, Maria, et al.
Publicado: (2022)

Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy
por: Arsenic, Ruza, et al.
Publicado: (2015)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids
por: Prasad, Vikas, et al.
Publicado: (2015)

Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS
por: Jäkel, Bianka, et al.
Publicado: (2021)

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens
por: Schossig, Paul, et al.
Publicado: (2023)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms
por: Kaemmerer, Daniel, et al.
Publicado: (2014)

Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study
por: Scheibenbogen, Carmen, et al.
Publicado: (2021)

Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
por: Albert, Veruschka, et al.
Publicado: (2022)

Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies
por: Kleo, Karsten, et al.
Publicado: (2022)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption
por: Tölle, Markus, et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

An Overview of Bortezomib-Induced Neurotoxicity
por: Meregalli, Cristina
Publicado: (2015)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1ibji3rnfd2l3rk8uf5angq36s